About us Contacts Drug interactions: 390 212
Drug search by name

Kaletra Oral Solution and Upadacitinib

Determining the interaction of Kaletra Oral Solution and Upadacitinib and the possibility of their joint administration.

Check result:
Kaletra Oral Solution <> Upadacitinib
Relevance: 05.01.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased. MANAGEMENT: Caution is recommended if upadacitinib is used with potent CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy. References "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.

Professional:

MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of upadacitinib, which is primarily metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased upadacitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 70% and 75%, respectively. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.

MANAGEMENT: Caution is recommended if upadacitinib is used with potent CYP450 3A4 inhibitors. Pharmacologic effects of upadacitinib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy.

References
  • "Product Information. Rinvoq (upadacitinib)." AbbVie US LLC, North Chicago, IL.
Kaletra Oral Solution

Generic Name: lopinavir / ritonavir

Brand name: Kaletra

Synonyms: Kaletra

Upadacitinib

Generic Name: upadacitinib

Brand name: Rinvoq

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction